Certain Sglt2 Inhibitors Glp1 Ras For T2dm Also Cut Cv Risk | Latest News RSS feed

Certain Sglt2 Inhibitors Glp1 Ras For T2dm Also Cut Cv Risk - Latest News


Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

(HealthDay News) — Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be ... read more

November 2018 Briefing - Pharmacy

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk THURSDAY, Nov. 29, 2018 (HealthDay News) -- Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor ... read more

November 2018 Briefing – Diabetes & Endocrinology

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk THURSDAY, Nov. 29, 2018 (HealthDay News) — Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor ... read more

Looking for another news?


Intensive Diabetes Treatment Reduces Complications, Ups Survival

The median time to first cardiovascular event was 8.1 years longer in the intensive-therapy group, and the risk for all microvascular complications was decreased in the intensive-therapy group with th... read more


Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients

Beyond loss of mobility, sufferers face a high risk of heart failure. An inflammatory cytokine known for contributing to the development of RA, tumor necrosis factor ... but also prevent joint damage. ... read more

PT/INR Monitoring Systems Being Pulled from Market

The Company initiated a voluntary correction in December 2014 to inform users of the INRatio and INRatio 2 PT/INR Monitoring System that patients with certain medical conditions should not be tested w... read more

Whey Protein Breakfast Aids Glycemic Control in Type 2 Diabetes

BOSTON — Adults with type 2 diabetes who start the day with a large breakfast that ... Greater reductions in HbA1c were also noted among these patients, with the percent change being 11.5% for the whe... read more

Certain SGLT2 inhibitors, GLP-1 RAs for T2DM also cut CV risk

(HealthDay)—Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used f... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us